| Item |
Information |
|
Drug Groups
|
approved; investigational |
|
Description
|
Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. |
| Indication |
For the treatment of Paget's disease of the bone (osteitis deformans), postmenopausal and glucocorticoid-induced osteoporosis |
| Pharmacology |
Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism and is indicated for the treatment and prevention of osteoporosis in postmenopausal women. |
| Toxicity |
Side effects include abdominal pain, anxiety, back pain, belching, bladder irritation, bone disorders and pain, bronchitis, bursitis, cataracts, chest pain, colitis, constipation, depression, diarrhea, difficulty breathing, dizziness, dry eyes, eye infection, flu-like symptoms, gas, headache, high blood pressure, infection, insomnia, itching, joint disorders and pain, leg cramps, muscle pain, muscle weakness, nausea, neck pain, nerve pain, pain, pneumonia, rash, ringing in ears, sinus problems, sore throat, stomach bleeding, stuffy or runny nose, swelling, tendon problems, tumor, ulcers, urinary tract infection, vertigo, vision problems, and weakness. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
No evidence found for metabolization of risedronate in humans or mammals |
| Absorption |
Rapid absorption (~1 hr) after an oral dose, occurs throughout the upper gastrointestinal tract |
| Half Life |
1.5 hours |
| Protein Binding |
~24% |
| Elimination |
Risedronate is excreted unchanged primarily via the kidney. Insignificant amounts (<0.1% of intravenous dose) of drug are excreted in the bile in rats. |
| Distribution |
* 13.8 L/kg |
| Clearance |
* 122 mL/min
* 73 mL/min [osteopenic postmenopausal women] |
| External Links |
|
|